Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms by Koh, Cheryl M. et al.
www.impactjournals.com/oncotarget/  Oncotarget, September, Vol.2, No 9
Oncotarget 2011; 2:  669 - 683 www.impactjournals.com/oncotarget 669
Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia 
via Transcriptional and Post-transcriptional Mechanisms
Cheryl M. Koh1, Tsuyoshi Iwata1, Qizhi Zheng1, Carlise Bethel1, Srinivasan 
Yegnasubramanian2,3,4,5, Angelo M. De Marzo1,2,3,4,5
Departments of Pathology1, Urology2, Oncology3, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4 and 
The Brady Urological Research Institute5, The Johns Hopkins University, School of Medicine, Baltimore, MD, USA
Correspondence to:  Angelo M De Marzo, email: ademarz@jhmi.edu
Keywords: Myc, EZH2, prostate cancer
Received:  September 13, 2011, Accepted: September 19, 2011, Published: September 19, 2011
Copyright: © Koh et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which per-
mits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
EZH2 is part of the PRC2 polycomb repressive complex that is overexpressed in 
multiple cancer types and has been implicated in prostate cancer initiation and 
progression. Here, we identify EZH2 as a target of the MYC oncogene in prostate 
cancer and show that MYC coordinately regulates EZH2 through transcriptional and 
post-transcriptional means. Although prior studies in prostate cancer have revealed 
a number of possible mechanisms of EZH2 upregulation, these changes cannot 
account for the overexpression EZH2 in many primary prostate cancers, nor in most 
cases of high grade PIN. We report that upregulation of Myc in the mouse prostate 
results in overexpression of EZH2 mRNA and protein which coincides with reductions 
in miR-26a and miR-26b, known regulators of EZH2 in some non-prostate cell types, 
albeit not in others. Further, in human prostate cancer cells, Myc negatively regulates 
miR-26a and miR-26b via direct binding to their parental Pol II gene promoters, 
and forced overexpression of miR-26a and miR-26b in prostate cancer cells results 
in decreased EZH2 levels and suppressed proliferation. In human clinical samples, 
miR-26a and miR-26b are downregulated in most primary prostate cancers. As a 
separate mechanism of EZH2 mRNA upregulation, we find that Myc binds directly to 
and activates the transcription of the EZH2 promoter. These results link two major 
pathways in prostate cancer by providing two additional and complementary Myc-
regulated mechanisms by which EZH2 upregulation occurs and is enforced during 
prostatic carcinogenesis. Further, the results implicate EZH2-driven mechanisms 
by which Myc may stimulate prostate tumor initiation and disease progression. 
INTRODUCTION
EZH2 is a histone lysine methyltransferase that 
is part of the PRC2 polycomb repressive complex. It 
catalyzes the tri-methylation of histone 3 on lysine 27 
(H3K27me3), which is involved in chromatin remodeling 
and the silencing of genes, including homeobox genes 
involved in differentiation [1-4]. EZH2 is overexpressed 
during prostate cancer progression [5, 6] and promotes 
proliferation, invasion, tumor formation, and metastasis 
of prostate cancer cells, and is considered to be involved 
in the progression to advanced disease [7-11]. Prior 
studies indicated that at least three separate mechanisms 
could result in EZH2 upregulation in prostate cancer. 
Saramäki et al. found that a region on chromosome 
7q36.1 harboring EZH2  is  amplified  in  approximately 
20% of castrate resistant prostate cancers [8]. More 
recently, Varambally et al. used a bioinformatics approach 
to nominate miR-101 as a potential microRNA that can 
target  EZH2 mRNA for silencing [5]. miR-101 was 
shown to specifically target EZH2 for down regulation 
in prostate cancer cells, and the miR-101 locus was 
deleted in 37.5% of localized prostate cancers and 66.7% 
of castrate-resistant metastatic prostate cancer cases. 
Additionally, Yu et al. and Kunderfranco et al. reported 
that the ETS gene family members ERG and ESE3 could 
activate and repress EZH2 transcription, respectively 
[12, 13]. Interestingly, the original study by Varambally Oncotarget 2011; 2:  669 - 683 670 www.impactjournals.com/oncotarget
et al. documented upregulation of EZH2 in the majority 
of all prostate cancer cases, as well as in the majority of 
all high grade PIN, a key prostate cancer precursor lesion 
[6]. The findings published to date, therefore, can explain 
EZH2 upregulation in only a subset of cases of primary 
and metastatic prostate cancer, and the mechanisms by 
which EZH2 is upregulated in PIN lesions and in a subset 
of early carcinomas have not been fully elucidated. Thus, 
we hypothesized that additional mechanisms are likely 
operative that induce EZH2 upregulation in prostate 
cancer, at least during the early phases of the disease. 
MYC is one of the most commonly overexpressed 
oncogenes in cancer [14]. In prostate cancer, Myc 
overexpression is a frequent and early event, occurring 
in lesions of both high grade prostatic intraepithelial 
neoplasia (PIN), and localized and metastatic prostatic 
adenocarcinomas, suggesting that Myc contributes to 
the initiation and progression of the disease [15]. Myc 
is a pleiotropic transcription factor which is key in 
controlling the expression of genes involved in DNA 
replication, protein synthesis, cell cycle progression, 
cellular metabolism, chromatin structure, differentiation 
and stem cell fate [14, 16]. It was previously shown 
that Myc can activate and repress the expression of 
numerous miRNAs [17-20], hence providing additional 
mechanisms by which Myc can control gene expression. 
Studies carried out in lymphoma cells and hepatocelluar 
carcinoma cells have shown that Myc represses the 
expression of a number of miRNAs, including miR-26a 
and miR-26b [17, 21]. Interestingly, the 3’UTR of EZH2 
contains target sites for miR-26a and miR-26b, and EZH2 
was shown to be targeted for repression by miR-26a in 
muscle and lymphoma cells [21, 22], and of miR-26b 
in HeLa cells [23]. Hence, we hypothesized that Myc 
may be a key driver of EZH2 overexpression in PIN and 
prostate cancer lesions via repression of miR-26a and 
miR-26b. Further, since Myc is a well-known sequence 
specific transacting factor that binds to promoter regions 
and regulates transcription of a relatively large number 
of target genes, we also investigated whether Myc can 
directly transactivate EZH2 transcription as well. 
MATERIALS AND METHODS
Animal studies
The experimental protocol was approved by the 
Animal Care and Use Committee at Johns Hopkins 
University, and the animals were cared for in accordance 
with institutional guidelines. The Lo-MYC transgenic 
mice used in this study were obtained from the Mouse 
Repository of the National Cancer Institute Mouse Models 
of Human Cancer Consortium at NCI Frederick, MD, 
USA, and were maintained as previously described [24].
Cell Culture
The human prostate cancer cell lines LNCaP, 
CWR22rv1, DU145 and PC3, were obtained from the 
American Type Culture Collection (ATCC). MYC-CaP 
cells were a generous gift from Charles Sawyers [25]. They 
were maintained at 37oC and 5% CO2, and supplemented 
with RPMI 1640 or DMEM with 10% serum. 
Transfections
Cells were transfected using Oligofectamine or 
Lipofectamine 2000 (Invitrogen). MYC siRNA pools 
(Dharmacon, L-003282), siCONTROL Non-Targeting 
siRNA pool #1 (Dharmacon, D-001810), miRIDIAN 
Mimic hsa-mir-26a (Dharmacon, C-300499), miRIDIAN 
Mimic hsa-mir-26b (Dharmacon, C-300501) and 
miRIDIAN microRNA Mimic Negative Control #1 
(Dharmacon CN-001000) were  transfected  at  a  final 
concentration of 50nM. 
Quantitative Real-time PCR
RNA was isolated from cells using miRNeasy 
kit (Qiagen), and from tissue sections using Trizol 
(Invitrogen). cDNA was synthesized using the RetroScript 
kit (Ambion). Quantitative RT-PCR was carried out using 
iQ SYBR Green Supermix (Biorad). PCR primers are 
shown in Supplementary Table 1. The relative amount 
of the gene of interest was determined using the  Ct 
method, relative to TBP and to the control cells, or matched 
normal tissue. Mature miR-26a and miR-26b expression 
was measured by Taqman assay (Applied Biosystems) 
according to manufacturer’s instructions, and normalized 
against U6 expression. Four independent knockdown 
experiments were carried out, and triplicate quantitative 
PCR experiments were done for each condition. Data was 
Log2 transformed and error bars represent the standard 
deviation.
Western Blotting
Cells and tissues were lysed in RIPA buffer and stored 
at -80oC. Lysates were separated on SDS-PAGE gels and 
electrophoresed onto PVDF membranes. Membranes 
were probed with antibodies against EZH2 (Epitomics, 
1:2000) and tubulin (Calbiochem CP06, 1:2000) in 5% 
non-fat dry milk in TBST.
Chromatin Immunoprecipitation
ChIP was carried out using the rabbit polyclonal 
anti-MYC antibody (Santa Cruz, sc-764), as previously Oncotarget 2011; 2:  669 - 683 671 www.impactjournals.com/oncotarget
described [26]. Primers are listed in Supplementary Table 
1.
Cell Proliferation Assays
Cells were stained with 0.4% trypan blue, and the 
number of viable cells was counted using a hemocytometer.
Luciferase Reporter Assays
The complete and truncated EZH2 3’ UTR were 
amplified using the primers listed in Table S1. They were 
cloned into the pMIR-REPORT™ miRNA Expression 
Reporter Vector System (Ambion) between the HindIII 
and SpeI sites. The EZH2 promoter reporter vector 
(S111151) was purchased from SwitchDB. The reporter 
promoters were transfected along with a Renilla control 
plasmid, and either non-targeting siRNA, MYC siRNA, 
miR-26a mimics, or miR-26b mimics. Luciferase 
activity was measured 24 hours after transfection using 
the Dual-luciferase reporter assay system (Promega). 
Three independent experiments were carried out, with 4 
replicates for each condition.
Immunohistochemistry (IHC)
Immunohistochemistry was done with the Power 
Vision+ poly-HRP IHC Kit (ImmunoVision Inc). Slides 
were steamed for 40 minutes in EDTA solution (Zymed) 
and incubated with mouse anti-EZH2 antibody (BD 
Figure 1: Elevated EZH2 Expression in the Lo-MYC Murine Model of Prostate Cancer. (A) Increased EZH2 protein 
expression in the ventral prostates of Lo-MYC mice (right panel), as compared to wild type controls (left panel). (B) Semi-quantitative 
image analysis of EZH2 protein expression in 9 wild type and 14 Lo-MYC mice. EZH2 expression was elevated in PIN, cribriform PIN/ 
CIS, and invasive adenocarcinoma lesions, as compared to normal prostate. (C) EZH2 mRNA is elevated in PIN lesions from the ventral 
prostates of Lo-MYC (6 mice), as compared to ventral prostates from age-matched wildtype FVB mice (3 mice). 
A
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Transduction) overnight. Poly-HRP-conjugated anti-
mouse/rabbit IgG antibody was used as secondary antibody. 
Staining was visualized using 3,3’-Diaminobenzidine 
(Sigma) and slides were counterstained with hematoxylin.
Quantitative Image Analysis
Scanned images were analyzed using FriDA as 
previously described [15].
Tissues
This study was approved by The Johns Hopkins 
University School of Medicine institutional review board. 
Matched normal and tumor pairs were obtained from 
frozen sections from radical prostatectomy specimens.   
Specimens comprised Gleason scores 6 and 7, and stages 
from T2N0Mx to T3BN0Mx (Table S2).
Statistics
Students t-test was performed to determine 
statistical significance and p-values are indicated in the 
text. Changes are also indicated in the figures where (*) 
represents p <0.05.
RESULTS
A
B
C
Figure 2: Correlation between MYC and EZH2 expression in primary prostate cancer specimens. (A) Western blot 
showing increased EZH2 protein expression in localized prostate cancer specimens, as compared to matched normal tissue. (B) Elevated 
EZH2 mRNA levels in localized prostate cancer specimens, as compared to matched normal tissue, determined by quantitative real-time 
PCR. (C) Positive correlation between the expression of MYC and EZH2 mRNA levels. Oncotarget 2011; 2:  669 - 683 673 www.impactjournals.com/oncotarget
MYC regulates EZH2 in the Lo-MYC murine 
model of prostate cancer
The Lo-MYC transgenic mouse model recapitulates 
the molecular and histological phenotype of early human 
prostate cancer formation [24, 27]. In this model, Myc 
overexpression in the prostate induces the morphologically 
distinguishing features of PIN, including nuclear and 
nucleolar enlargement, an increase in mitotic figures, as 
well as widespread chromatin remodeling. Using these 
mice for immunohistochemical staining, we observed 
that the expression of EZH2 protein was barely detectable 
in control non-transgenic littermate mice, but that levels 
were markedly upregulated in PIN lesions in the Lo-
MYC mice (Fig. 1A). Similar to overexpression of Myc, 
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Figure 3: Myc binds to the EZH2 promoter region and activates EZH2 transcription in prostate cancer cell lines. (A) 
Reduced EZH2 protein (Left Panel) and mRNA (Right Panel) expression following siRNA-mediated MYC depletion. (B) Enrichment of 
Myc binding at the E-box-containing promoter region of EZH2 in 2 prostate cancer cell lines, as determined by ChIP. Immunoprecipitation 
was carried out with an anti-Myc antibody (black bars) and a control IgG antibody (white bars). (C) Decreased EZH2 promoter activity 
after MYC depletion (black bars), as compared to control cells (white bars) in human prostate cancer cell lines.Oncotarget 2011; 2:  669 - 683 674 www.impactjournals.com/oncotarget
the increased expression of EZH2 protein in PIN lesions 
was confined to luminal epithelial cells. Semi-quantitative 
image analysis showed that as compared to wild-type 
mice, there was a marked increase in expression of EZH2 
in PIN lesions, cribriform PIN lesions and early invasive 
adenocarcinoma lesions in the transgenic mice (Fig. 1B). 
Similar results were obtained in a number of Hi-MYC 
mice (not shown). Next, used quantitative real time RT-
PCR and found that EZH2 mRNA was also increased in 
the Myc-overexpressing transgenic mice, compared to the 
wild type controls (Fig. 1C, p<0.03). Thus, in these Myc-
driven murine models of prostate cancer, EZH2 elevation 
occurs downstream of Myc induction. 
MYC and EZH2 are overexpressed in primary 
prostate cancer specimens
It has been shown that EZH2 is overexpressed in 
prostate cancer, particularly in aggressive metastatic 
cases [6]. We prepared crude whole cell lysates from 5 
matched benign and primary prostate cancer specimens 
and verified that EZH2 protein expression was elevated in 
the tumors (Fig. 2A). Next, we obtained mRNA from 18 
matched normal and primary prostate cancer specimens 
(Table S2) and confirmed that MYC and EZH2 mRNA 
were indeed overexpressed in the prostate cancers 
(Wilcoxon signed ranked test, p<0.0002 for both) (Fig. 
2B, S1A). Additionally, in these same specimens there 
was a significant positive correlation between MYC and 
EZH2 mRNA expression (Spearman rank correlation 
coefficient= 0.7115, p<0.0001) (Fig. 2C). 
MYC regulates EZH2 mRNA and protein 
expression in prostate cancer cell lines
We used siRNA-mediated knockdown to deplete 
Myc in 4 human prostate cancer cell lines- DU145, 
PC3, LNCaP and CWR22rv1, as well as in the MYC-
CaP cell line, which was derived from the Hi-MYC 
transgenic mouse model [25]. We have recently shown 
approximately 50-70% of Myc protein could be reduced 
using these siRNA transfection conditions in each of these 
cell lines [28]. 72h after Myc knockdown, we measured 
the expression of EZH2 mRNA by quantitative real time 
PCR, relative to the expression of TBP, and found it to 
be reduced by 30%-60% (p<0.05) (Fig. 3A, right panel). 
Accordingly, as compared to control cells that were 
transfected with non-targeting siRNA, EZH2 protein 
was also reduced in cells that had been transfected with 
siRNA targeting Myc (Fig. 3A, left panel). By microarray 
analyses, we observed an induction of CDH1 and ADRB2, 
known EZH2 target genes, following MYC depletion in 
LNCaP and DU145 cells (Fig. S1B).
By examining publically available data in the 
UCSC genome browser database, Myc was observed to 
associate upstream of the EZH2 transcription start site in 
K562 human myelogenous leukaemia cells and GM12878 
lymphoblastoid cells (Figure S1C). To address whether 
EZH2 is a direct target of transcriptional activation 
by Myc in prostate cancer, we carried out chromatin 
immunoprecipitation (ChIP), and enriched Myc binding 
approximately 1kb and 2kb upstream of the transcription 
start site of EZH2, which contains a canonical E-box 
(Figure 3B). With increasing distance upstream of the 
EZH2 transcription start site (approximately -4kb), 
there was no significant enrichment of Myc binding. To 
determine if EZH2 is a direct MYC target gene, we used 
firefly luciferase as a reporter of EZH2 promoter activity. 
In DU145 and PC3 cells that had been depleted of MYC 
by siRNA-mediated knockdown, we observed reduced 
EZH2 promoter activity (Fig. 5B; p<0.02 for both cell 
lines),indicating that MYC can indeed activate EZH2 
transcription in prostate cancer cell lines.
Myc represses miR-26a and miR-26b expression
Myc was previously reported to regulate the 
expression of miRNAs [17], including miR-26a and 
miR-26b in P493 lymphoma cells, by direct binding to 
their host Pol II gene promoters (CTDSPL,  CTDSP2, 
CTDSP1). However, such regulation has not been 
evaluated in prostate cancer. Since regulation of target 
genes by Myc can be cell type and context specific, we 
determined whether similar mechanisms were operative 
in prostate cancer cells. siRNA-mediated MYC depletion 
in 4 human prostate cancer cell lines was followed by 
quantitative real-time PCR to measure the expression 
of the mature miR-26a, its 2 primary forms, mir-26a1, 
and mir-26a2, as well as the host genes in which they 
are embedded, CTDSPL and CTDSP2. Additionally, we 
measured the expression of the mature and primary forms 
of miR-26b, and CTDSP1, the gene which harbors miR-
26b. Following MYC-depletion, we found a coordinate 
increase in the mRNA levels of CTDSPL, CTDSP2 and 
CTDSP1, and both the mature and primary forms of miR-
26a and miR-26b in all 4 cell lines (p<0.02 for all) (Fig. 
4A). To determine if MYC may be directly regulating miR-
26a via repression of CTDSPL and CTDSP2, and miR-
26b via repression of CTDSP1, we carried out chromatin 
immunoprecipitation on LNCaP and PC3 cells. We found 
a  significant  enrichment  of  MYC  at  the  promoters  of 
CTDSPL, CTDSP2 and CTDSP1 in both prostate cancer 
cell lines (Fig. 4B). MYC was previously reported to 
associate with these promoters in P493 lymphoma cells 
[17]. In terms of Lo-MYC mice, we found that levels of 
both miR-26a and miR-26b were reduced in PIN lesions 
as compared to normal epithelium in wild type controls 
(p<0.0005 for both) (Fig. 4C). Further, miR-26a and miR-
26b expression was increased in MYC-CaP cells after 
MYC depletion (p<0.02 for both) (Fig. 4D). Therefore, 
the regulation of these miRNAs by MYC occurs in both Oncotarget 2011; 2:  669 - 683 675 www.impactjournals.com/oncotarget
mouse and human prostatic cancer cells. 
EZH2 is a target of miR-26a and miR-26b in 
prostate cancer
Previous work in muscle, lymphoma and HeLa cells 
have shown that miR-26a and miR-26b can negatively 
regulate EZH2 expression, and that this occurs via binding 
to the highly conserved predicted miR-26a/b binding site 
within the 3’ UTR of EZH2 [21-23]. However, miR-26a 
did not regulate EZH2 in breast cancer or acute myeloid 
leukemia cells [5, 29], indicating that miRNA-regulation 
of target gene expression may be tissue and/or context 
specific. To determine if mir-26a and miR-26b can target 
EZH2 in prostate cancer cells, we transfected miR-26a and 
miR-26b mimics into one mouse and four human prostate 
cancer cell lines. We observed a reduction in EZH2 mRNA 
levels in all 5 cell lines (p<0.05), and a similar decrease 
in EZH2 protein following transient overexpression of 
miR-26a and miR-26b (Fig 5A, B). In the Lo-MYC mouse 
model, there was a significant negative correlation between 
the expression of EZH2 mRNA and miR-26a (Spearman 
rank correlation coefficient= -0.8667, p=0.0045), as well 
as EZH2 mRNA and miR-26b (Spearman rank correlation 
coefficient=  -0.8167,  p=0.0108)  (Fig.  S2A). To verify 
specific  associations  between  miR-26a  and  miR-26b 
and their predicted binding site on the EZH2 3’UTR in 
prostate cancer cells, we cloned the 3’UTR of EZH2 
into a luciferase reporter vector [21]. Co-transfection 
with either miR-26a mimics, miR-26b mimics or Myc 
siRNA resulted in reduced reporter activity, as compared 
to transfection with a non-targeting miR (p<0.03) (Fig. 
5C). As an additional control, we generated a luciferase 
reporter vector with a truncated EZH2 3’UTR, which 
lacks the miR-26a/b binding site. Using this construct, 
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Figure 4: Myc Regulates miR-26a and miR-26b in Human and Murine Prostate Cancer Cells. (A) (Upper Panel) Induction 
of miR-26a, its primary forms miR-26a1 and miR-26a2, and the genes in which they are embedded, CTDSPL and CTDSP2, following 
siRNA-mediated Myc depletion. (Lower Panel) Induction of miR-26b, its primary form, and the gene in which it is embedded, CTDSP1. 
(B)  Enriched Myc binding was observed at the promoter regions of CTDSPL, CTDSP2 and CTDSP1. Immunoprecipitation was carried out 
with an anti-Myc antibody (black bars) and a control IgG antibody (white bars). (C) Reduced miR-26a (Left Panel) and miR-26b (Right 
Panel) expression in the Lo-MYC mice, as compared to wildtype controls. (D) Induction of miR-26a and miR-26b after Myc depletion in 
MYC-CaP cells.Oncotarget 2011; 2:  669 - 683 676 www.impactjournals.com/oncotarget
there  was  no  significant  reduction  in  reporter  activity 
following co-transfection with miR-26a mimics, miR-
26b mimics or Myc siRNA (Fig. 5C). There was also was 
an induction of CDH1 and ADRB2, known EZH2 target 
genes, following miR-26a and miR-26b overexpression in 
LNCaP cells (Fig. S2B).
To determine the biological relevance of miR-
26a and miR-26b in prostate cancer cells, we assessed 
the effect of miR-26a and miR-26b transfection on the 
proliferation of 4 human prostate cancer cell lines and 
the Myc-driven mouse prostate cancer cell line. In all cell 
lines, proliferation was suppressed (p<0.01) (Fig. 5D). 
This suggests that Myc-mediated repression of miR-26a 
and miR-26b may be an important factor in maintaining 
the proliferative capacity of prostate cancer cells.
MYC, EZH2 and miR-26a expression in localized 
prostate cancer samples.
Next, to determine the relevance of miR-26a 
and miR-26b in clinical prostate cancer, we measured 
their expression in 18 matched normal and primary 
prostate cancer specimens (Table S2) and found both 
to be downregulated in cancer in most cases (Wilcoxon 
signed  rank  test,  p=0.0005  for  miR-26a,  p=0.079  for 
miR-26b) (Fig. 6A, Fig. S3A). There was a significant 
inverse correlation between the expression of MYC and 
miR-26a (Spearman rank correlation coefficient= -0.357, 
p=0.032),  while  that  for  MYC and miR-26b did not 
achieve statistical significance (Fig. 6B, Fig. S3B). We 
also  observed  significant  inverse  correlations  between 
miR-26a and EZH2 mRNA (Spearman rank correlation 
coefficient= -0.516, p=0.0013), and miR-26b and EZH2 
mRNA (Spearman rank correlation coefficient= -0.3552, 
p<0.0392) (Fig. 6C, Fig. S3C).
DISCUSSION
EZH2 mRNA and protein levels are elevated during 
progression of a number of types of cancer, including 
breast and prostate cancer [6, 30-32]. Further, several 
studies have shown oncogenic activity for EZH2 in a range 
of tumor cell types [2, 9, 33]. Prior to the present study, 
three molecular mechanisms were identified that could 
be responsible for overexpression of EZH2 in prostate 
cancer--amplification of the EZH2 gene [8], the deletion 
of its negative regulator miR-101 [5], and transcriptional 
regulation of EZH2 by ETS gene family members [12, 
Figure 4: Myc Regulates miR-26a and miR-26b in Human and Murine Prostate Cancer Cells. (C) Reduced miR-26a (Left 
Panel) and miR-26b (Right Panel) expression in the Lo-MYC mice, as compared to wildtype controls. (D) Induction of miR-26a and miR-
26b after Myc depletion in MYC-CaP cells.
C
DOncotarget 2011; 2:  669 - 683 677 www.impactjournals.com/oncotarget
13]. Interestingly, two of these mechanisms (EZH2 
amplification  and  miR-101  deletion)  are  encountered 
more frequently in advanced and castrate resistant prostate 
cancers than in primary untreated prostate cancers, and 
ETS family gene fusions and ERG protein overexpression 
are rarely seen in isolated PIN lesions or PIN lesions 
associated with ERG-negative carcinomas [34]. While 
EZH2 elevation is most marked in advanced/ castrate 
resistant metastatic lesions, EZH2 is also very commonly 
overexpressed in almost all human PIN and early prostate 
cancer lesions [6]. Whether EZH2 overexpression is 
also regulated by other mechanisms in PIN and primary 
prostate cancer lesions has not previously been examined. 
Here, we show that Myc induces overexpression of EZH2 
by two independent yet complementary mechanisms, and 
that this overexpression is seen in PIN lesions in Lo-MYC 
and Hi-MYC mice, as well as in human tissue samples. 
Since Myc is commonly overexpressed in human PIN and 
early carcinoma lesions, it is likely that overexpression of 
Myc is a key driver of EZH2 overexpression during the 
early phases of prostate cancer formation. Additionally, 
since Myc is also overexpressed, and commonly shows 
elevated gene copy number in advanced/hormone 
refractory prostate cancers, these results also provide 
additional mechanisms by which EZH2 overexpression 
may occur and/or be maintained at this stage of the disease. 
Using 5 prostate cancer cell lines (4 human, 1 
mouse), we showed that Myc depletion by siRNA results 
in decreased EZH2 mRNA and protein. It was previously 
reported that p53 can suppress EZH2 [35], and that E2F 
can induce EZH2 [36], but little is otherwise known about 
the direct transcriptional regulation of EZH2. Using ChIP, 
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Figure 5: MiR-26a and miR-26b Regulate EZH2 Expression in Human and Murine Prostate Cancer Cells. (A,B) MiR-
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we determined in 2 prostate cancer cell lines that MYC 
directly associates with the E-box-containing promoter 
region of EZH2. While this manuscript was in process, 
Salvatori et al. reported similar findings in acute myeloid 
leukemia, showing that Myc directly binds upstream of 
EZH2 and activates its transcription [29]. While EZH2 
expression was shown to regulate MYC expression in 
a glioma tumor model [37], it is clear in the Lo-MYC 
mouse model that MYC is elevated prior to EZH2 
overexpression. 
Since Myc is known to regulate miRNAs, in addition 
to mRNAs, we sought to determine Myc -responsive 
miRNAs in prostate cancer. MiR-26a and miR-26b have 
been reported to be Myc -repressed in lymphoma cells [17, 
21]. By quantitative real-time PCR, we found that Myc 
represses miR-26a and miR-26b in all prostate cancer cell 
lines studied. Additionally, we observed decreased miR-
26a and miR-26b expression in the Lo-MYC mice, as 
compared to the wildtype controls. In LNCaP and PC3 
cells, we observed an enrichment of Myc binding at the 
promoter regions of CTDSPL,  CTDSP2 and CTDSP1, 
genes whose introns harbor the miR-26a and miR-26b 
primary transcripts. EZH2 is a reported target of miR-
26a in muscle and lymphoma cells [21, 22], and of miR-
26b in HeLa cells [23]. In prostate cancer cells, we found 
that both miR-26a and miR-26b repressed both EZH2 
mRNA and protein. Further, using heterologous reporter 
constructs we found that the conserved miR-26a/b 
binding site within the 3’ UTR of EZH2 was required for 
this repression. As such, Myc may contribute to EZH2 
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Figure 5: MiR-26a and miR-26b Regulate EZH2 Expression in Human and Murine Prostate Cancer Cells. (C) miR-26a 
and miR-26b bind to the 3’UTR of EZH2 in prostate cancer cells. (D) Reduced proliferation of prostate cancer cell lines after transfection 
with miR-26a (dotted lines) and miR-26b (dashed lines), as compared to control miR (solid lines). Oncotarget 2011; 2:  669 - 683 679 www.impactjournals.com/oncotarget
elevation in prostate cancer, by directly activating EZH2 
transcription, and by repressing its negative regulators, 
miR-26a and miR-26b. Previously, Cao et al. reported 
that overexpression of miR-26a reduced EZH2 expression 
in DU145, but not PC3 or LNCaP cells, even though 
miR-26a inhibited the expression of a reporter construct 
containing the 3’UTR of EZH2 in all three cell lines [38]. 
This somewhat discrepant finding from ours may be a 
result of different transfection conditions or time points at 
which samples were harvested.
In our set of matched primary prostate cancer 
specimens and normal prostate tissue, we found MYC 
and EZH2 elevation, and a positive correlation between 
the expression of the two genes. EZH2 was reported to 
positively regulate MYC in glioblastoma cells [37]. 
Hence, this may set up a feed-forward loop that sustains 
high levels of Myc and EZH2, thus deregulating these 
central regulatory nodes and promoting transformation, 
and contributing to the oncogenic phenotype.
Reduced miR-26a expression has been noted in 
various cancers, including hepatocellular carcinoma, 
thyroid anaplastic carcinoma, rhabdomyosarcoma and 
B
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Figure 6: MiR-26a Expression in Primary Prostate Cancer Specimens. (A) Reduced miR-26a expression in primary prostate 
cancer cases, normalized to matched benign prostate tissue. Inverse correlations were observed between MYC and miR-26a/b (B), as well 
as miR-26a/b and EZH2 (C).Oncotarget 2011; 2:  669 - 683 680 www.impactjournals.com/oncotarget
clear cell renal cell carcinoma [39-44]. However, miR-
26a has been reported to be amplified in gliomas, and to 
promote gliomagenesis [43]. Previous miRNA profiling 
studies in prostate cancer have reported both the down-
regulation [45, 46], and the up-regulation of miR-26a [47-
49]. Decreased miR-26b expression has been reported in 
liver, head and neck cancers, and in hormone refractory 
prostate cancer [46, 50, 51], while its upregulation was 
reported in bladder cancer [52]. Thus, whether miR-26a 
and miR-26b facilitate oncogenesis, or act as a tumor 
suppressor, may depend on the cellular context. 
By quantitative real-time PCR, we found that the 
expression of miR-26a was reduced in a high fraction of 
localized prostate cancer, and correlated negatively with 
the expression of both MYC and EZH2. In general, miR-
26b expression was also reduced in the tumors, though 
B
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Figure 7: Model of Regulation of EZH2 by Myc by Two Distinct Mechanisms in Prostate Cancer. (A) In normal prostate 
luminal cells, Myc protein expression is low. Myc-induced EZH2 transcription occurs at a low level, resulting in basal expression levels of 
EZH2. Since MYC represses the transcription of CTDSPL, CTDSP2 and CTDSP1, when MYC levels are low, these genes, which harbor 
miR-26a and miR-26b, are actively transcribed. MiR-26a and miR-26b are incorporated into the RISC complex and bind specifically to 
their complementary site on the 3’ UTR of EZH2, destabilizing EZH2 mRNA and repressing its translation. As such, EZH2 is maintained 
at a low level by transcriptional and post-transcriptional regulatory mechanisms. (B) In prostate cancer, elevated Myc levels drive EZH2 
overexpression. MYC binds to the E-box-containing promoter region of EZH2 and activates its transcription. Concurrently, MYC represses 
CTDSPL, CTDSP2 and CTDSP1, in which miR-26a and miR-26b are embedded. As such, miRNA-mediated post-transcriptional silencing 
of EZH2 mRNA is reduced. This results in elevated EZH2 protein expression.Oncotarget 2011; 2:  669 - 683 681 www.impactjournals.com/oncotarget
this reduction was not as consistent. Transient transfection 
of miR-26a and miR-26b mimics into 5 prostate cancer 
cell lines resulted in suppressed proliferation, indicating 
that these MYC targets of repression may have tumor-
suppressive functions in the context of prostate cancer. In 
a murine liver cancer model, in which a similar under-
expression of miR-26a was observed, targeted delivery of 
miR-26a showed a therapeutic effect [40]. Thus, similar 
strategies may be applicable to the treatment of prostate 
cancer. 
In summary, we report that Myc can activate EZH2 
expression in prostate cancer by 2 distinct mechanisms- 
via direct transcriptional activation of the EZH2 promoter, 
as well as via repression of miR-26a and miR-26b, which 
themselves can repress EZH2. The frequent and early 
overexpression of Myc in PIN and primary prostate cancer 
cases may account in part for the common upregulation of 
EZH2 in these lesions. A model for how Myc regulates 
EZH2 is shown in Fig. 7. First, Myc upregulates EZH2 
directly by binding to the EZH2 promoter and stimulating 
its transcription. Second, by simultaneously binding to 
and inhibiting transcription of the host genes encoding 
miR-26a and miR-26b, Myc enforces this upregulation 
by inhibiting post-transcriptional silencing of EZH2 
mRNA. Thus, by binding to 4 separate loci and affecting 
both activation and repression, Myc coordinates the 
upregulation of EZH2 protein. 
These findings have additional implications for the 
transformation of prostate epithelial cells. For example, 
it is quite plausible that Myc may stimulate prostate 
cancer initiation, in part via EZH2-mediated chromatin 
remodeling and gene silencing. Hence, these results 
support the concept that EZH2 may be an early contributor 
to prostate cancer development [53], in addition to 
being a potent driver of the progression to aggressive, 
metastatic disease. EZH2 can modulate the expression 
of numerous regulatory networks, and there is significant 
enrichment for EZH2-mediated H3K27me3 polycomb 
repression signatures in embryonic stem cells, embryonic 
fibroblasts  and  advanced  prostate  cancer  [4,  13,  54]. 
Myc has also been shown to activate an embryonic stem 
cell-like module of gene expression and can prevent the 
terminal differentiation of prostate cancer cells (Koh et 
al., in preparation). Hence, Myc overexpression may drive 
prostate cancer initiation by perturbing normal prostate 
differentiation programs and aberrantly activate embryonic 
stem-cell like programs, in part by the induction of EZH2. 
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